BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29152083)

  • 21. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of PD-1 and its ligands in non-small cell lung cancer.
    Usluer O; Gökbayrak ÖE; Erol A; Aktaş TÇ; Batıhan G; Örs Kaya Ş; Üçvet A; Aydoğdu Z; Altun Z; Öztop İ; Aktaş S
    Turk Gogus Kalp Damar Cerrahisi Derg; 2024 Jan; 32(1):84-92. PubMed ID: 38545362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High proportions of PD-1
    Hollander P; Kamper P; Smedby KE; Enblad G; Ludvigsen M; Mortensen J; Amini RM; Hamilton-Dutoit S; d'Amore F; Molin D; Glimelius I
    Blood Adv; 2017 Aug; 1(18):1427-1439. PubMed ID: 29296784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
    Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
    Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis.
    Li S; Xia Z; Cao J; Zhang J; Chen B; Chen T; Zhang X; Zhu W; Li D; Hua W; Mao Y
    Front Immunol; 2022; 13():1039862. PubMed ID: 36439151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
    Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM
    Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
    Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
    Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.
    Miyasato Y; Takashima Y; Takeya H; Yano H; Hayano A; Nakagawa T; Makino K; Takeya M; Yamanaka R; Komohara Y
    J Clin Exp Hematop; 2018; 58(2):95-101. PubMed ID: 29998979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.
    Abrey LE; Ben-Porat L; Panageas KS; Yahalom J; Berkey B; Curran W; Schultz C; Leibel S; Nelson D; Mehta M; DeAngelis LM
    J Clin Oncol; 2006 Dec; 24(36):5711-5. PubMed ID: 17116938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy.
    Luo Q; Yang C; Fu C; Wu W; Wei Y; Zou L
    Front Oncol; 2021; 11():639644. PubMed ID: 33996552
    [No Abstract]   [Full Text] [Related]  

  • 39. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
    Kim KJ; Yang HK; Kim WH; Kang GH
    Oncotarget; 2017 Aug; 8(35):58887-58902. PubMed ID: 28938605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.